References
- Held P. J., Port F. K., Blagg C. R., Agoda L. Y.C. United States Renal Data System 1990 annual report. Am J Kidney Dis. Suppl 1990; 2: 1–106
- Mogensen C. E., Christensen C. K. Blood pressure changes and renal function changes in incipient and overt diabetic nephropathy. Hypertension 1985; 7: 1164–1173
- Cooper M. E., Allen T. J., O'Brien R., Clarke B., Jerums G., Doyle A. E. Effects of genetic hypertension on diabetic nephropathy in the rat — functional and structural characteristics. J Hypertension 1938; 6: 1009–1016
- Cooper M. E., Allen T. J., O'Brien R. C., Papazoglou D., Clarke B. E., Jerums G., Doyle A. E. Nephropathy in model combining genetic hypertension with experimental diabetes. Enalapril versus hydralazine and metoprolol therapy. Diabetes 1990; 39: 1575–9
- Anderson S., Rennke H. G., Brenner B. M. Nifedipine versus fosinopril in uninephrectomized diabetic rats. Kidney Int. 1992; 41: 891–7
- Bakris G. L. Renal effects of calcium antagonists in diabetes mellitus. An overview of studies in animal models and in humans. Am J Hypertens. 1991; 4: 487s–493s
- Zatz R., Dunn B. R., Meyer T. W., Brenner B. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest. 1986; 77: 1925–1930
- Rumble J. R., Doyle A. E., Cooper M. E. Comparison of effects of ACE inhibition with calcium channel blockade on renal disease in a model combining genetic hypertension with diabetes. Am J Hypertens. 1995; 8: 53–57
- Cooper M. E., Rumble J., Komers R., Du H. C., Jandeleit K., Chou S. T. Diabetes-associated mesenteric vascular hypertrophy is attenuated by angiotensin-converting enzyme inhibition. Diabetes 1994; 43: 1221–8
- Vranes D., Dilley R. D., Cooper M. E. Diabetes associated vascular hypertrophy is associated with endothelial proliferation. Diabetologia 1995; 38(suppl 1)A255
- Rumble J., Komers R., Cooper M. Kinins/nitric oxide are involved in the anti-trophic effects of ACE inhibitors on diabetes associated mesenteric vascular hypertrophy. J Hypertension 1996; 14: 601–607
- Gin T., Joon T., Panagiotopoulos S., Cooper M., Taylor H., Jerums G. Organ specificity of antihypertensive therapy on ocular albumin vascular clearance and albuminuria in the hypertensive diabetic rat. Investigative Ophthalmology & Visual Science 1996; 37: 281–289
- Anderson S., Rennke H. G., Garcia D. L., Brenner B. M. Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Inter. 1989; 36: 526–536
- Kasiske B., Kalil R., Ma J., Liao M., Keane W. Effect of antihypertensive therapy on the kidney in patients with diabetes: a metaregression analysis. Ann Intern Med. 1993; 118: 129–138
- Melbourne Diabetic Nephropathy Study Group Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. Br Med J. 1991; 302: 210–6
- Jerums G., Allen T. J., Tsalamandris C., Cooper M. E. Angiotensin converting enzyme inhibition and calcium channel blockade in incipient diabetic nephropathy. The Melbourne Diabetic Nephropathy Study Group. Kidney Int. 1992; 41: 904–11
- Gilbert R. E., Tsalamandris C., Bach L., Panagiotopoulos S., O'Brien R. C., Allen T. J., Goodall I., Young V., Seeman E., Murray R. M.L., Cooper M. E., Jerums G. Glycemic control and the rate of progression of early diabetic kidney disease: a nine year longitudinal study. Kidney Int. 1993; 44: 855–859
- Gilbert R., Jerums G., Allen T., Hammond J., Cooper M., Melbourne Diabetic Nephropathy Study Group. Effect of different antihypertensive agents on normotensive microalbuminuric patients with IDDM and NIDDM. J Am Soc Nephrol. 1994; 5: 377
- Rossing P., Hommel E., Smidt U., Parving H. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 1994; 37: 511–6